Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin study

This article was originally published in The Tan Sheet

Executive Summary

Peter Gann, MD, Northwestern University Medical School, et al., concluded that "regular aspirin use, at a dose adequate for preventing myocardial infarction, was not associated with a substantial reduction in the incidence of colorectal cancer during five years of randomized treatment and follow-up." Published in the Aug. 4 Journal of the National Cancer Institute, the study also inferred that low-dose aspirin users are not likely to have an increased incidence of colorectal cancer due to aspirin-induced G-I bleeding. However, Gann et al. recommended that additional epidemiologic studies and prevention trials be undertaken to assess the potential benefits of higher doses of aspirin or a longer duration of use.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081791

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel